Biden’s ‘Advanced Research’ Agency May Have Pros And Cons, Congressional Research Service Concludes

CRS poses series of questions about how a new federal agency tasked with speeding translational research for treating high-impact diseases would work, including potential downsides and whether it would duplicate government programs already in place.